|
Session 139-Poster Abstracts
ART Pharmacokinetics in Children
Wednesday, 2-4 pm; Hall A |
| 712 |
Population Pharmacokinetics of ATV/r in HIV-1+ Children and Adolescents
F Foissac1,2, S Blanche1,3, C Dollfus1, G Firtion4, D Hirt2, Jean-Marc Tréluyer*1,2,5,6, and S Urien1,2,5
1Univ Paris Descartes, France; 2Clin Res Unit Ctr, Paris, France; 3Hosp Necker, Paris, France; 4Hosp Cochin-St Vincent de Paul, Paris, France; 5INSERM 0901, Paris, France; and 6Hosp St Vincent de Paul, Paris, France |
| 713 |
ARIEL: 24-Week Safety and Efficacy of DRV/r in Treatment-experienced 3- to <6-Year-old Patients
Avy Violari*1, R Bologna2, R Kimutai3, N Kumarasamy4, JH Pilotto5, A Hendrickx6, G Kauwenberghs6, E Lathouwers6, T Van de Casteele6, and S Spinosa-Guzman6
1Univ of the Witwatersrand, Johannesburg, South Africa; 2Helios Salud, Buenos Aires, Argentina; 3Kenya Med Res Inst Wellcome Trust Res Prgm, Kilifi; 4YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India; 5Hosp Geral de Nova Iguaçu, Brazil; and 6Tibotec BVBA, Beerse, Belgium |
714
 |
Pharmacokinetics of DRV/r in Asian HIV-1+ 6-Year-old Children
K Chokephaibulkit1, W Prasitsuebsai2, O Wittawatmongkol1, M Gorowara2, W Phongsamart1, J Wongsabut2, N Vanprapar1, T Puthanakit2,3, D Burger4, Jintanat Ananworanich*2,3,5, on behalf of the HIV-NAT 113 Study Group
1Faculty of Med, Siriraj Hosp, Mahidol Univ, Bangkok, Thailand; 2HIVNAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 3Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand; 4Radboud Univ Nijmegen Med Ctr, The Netherlands; and 5South East Asia Res Collaboration with Hawaii, Bangkok, Thailand |
715
|
Interim Results from IMPAACT P1066: RAL Oral Chewable Tablet Formulation for 2- to 5-Year-olds
Sharon Nachman*1, E Acosta2, N Zheng2, H Teppler3, B Homony3, T Fenton1, E Handelsman4, C Worrell5, B Graham6, A Wiznia7, and P1066 Study Team
1State Univ of New York at Stony Brook, US; 2Univ of Alabama at Birmingham, US; 3Merck, North Wales, PA, US; 4Harvard Sch of Publ Hlth, Boston, MA, US; 5Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 6Frontier Sci and Tech Res Fndn, Buffalo, NY, US; and 7Jacobi Med Ctr, Bronx, NY, US |
| 716 |
Steady-state Pharmacokinetics of NVP Extended-release Formulation in Children with HIV-1 Infection
Carlo Giaquinto*1, G Anabwani2, C Feiterna-Sperling3, J Nutall4, K Mompati5, F Mensa6, C-L Yong6, J Sabo6, J Guo6, and A-M Quinson6
1Univ of Padua, Italy; 2Botswana-Baylor Children`s Clin Ctr of Excellence, Gaborone; 3Charité-Univ Med Berlin, Germany; 4Red Cross War Memorial Children`s Hosp, Cape Town, South Africa; 5Tati River Clin, Francistown, Botswana; and 6Boehringer Ingelheim Inc, Ridgefield, CT, US |
| 717 |
Factors Influencing Plasma NVP Levels: A Study in HIV-infected Children on Generic ART in India
AK Hemanth Kumar*1, G Ramachandran1, M Vasantha1, L Rajesh1, P Bhavani1, P Ganga Devi1, I Shah2, K Ramesh1, S Rajasekaran3, and S Swaminathan1
1Tuberculosis Res Ctr, Indian Council of Med Res, Chennai; 2BJ Wadia Hosp for Children, Mumbai, India; and 3Govt Hosp of Thoracic Med, Chennai, India |
718
|
Pharmacokinetics of ZDV Dosed Twice-daily according to WHO Weight-bands in African HIV-1+ Children
Quirine Fillekes*1, L Kendall2, S Kitaka3, P Mugyenyi4, P Musoke3, M Ndigendawani4, M Bwakura-Dangarembizi5, D Gibb2, D Burger1, S Walker2, on behalf of the ARROW Trial Team
1Radboud Univ Nijmegen Med Ctr, The Netherlands; 2MRC Clin Trials Unit, London, UK; 3Pediatric Infectious Disease Ctr, Mulago, Uganda; 4Joint Clin Res Ctr, Kampala, Uganda; and 5Univ of Zimbabwe Med Sch, Harare |
| 719 |
Developmental Pharmacokinetics of 3TC in 580 Pediatric Patients from Neonate to Adolescent
Naïm Bouazza*1,2, D Hirt1,2, S Blanche1,3, P Frange1,3, E Rey4, J-M Tréluyer1,2,4,5, and S Urien1,2,5
1Univ Paris Descartes, France; 2Hosp Tarnier, Paris, France; 3Hosp Necker, Paris, France; 4Hosp Cochin-St Vincent de Paul, Paris, France; and 5INSERM 0901, Paris, France |
|
